Dr. John Wizeman is an attorney in the firm’s Intellectual Property practice group, focusing his practice on biotechnology and life sciences matters.
John has been working at Lathrop GPM for more than four years, with a focus on antibodies and fusion proteins, including bispecific/multispecific antibodies and chimeric extended half-life fusion proteins. John has experience in multi-jurisdictional portfolio management, including SPC protection. In addition, John was a postdoctoral researcher at the University of Connecticut Health Center where he designed and conducted single-cell RNA sequencing experiments and led analysis of results using groundbreaking programming tools and developing analytical pipelines in the neuroscience field.